Profile data is unavailable for this security.
About the company
Sanofi India Limited is an India-based company, which is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company produces pharmaceutical formulations, dosage forms and offer a range of medicines across various therapeutic areas. Its product portfolio is focused on five therapeutic areas: diabetes, epilepsy, cardiology, allergy and pain care. In the diabetes area, the Company has an insulin portfolio under the brand name of Lantus, which helps in controlling high blood sugar in adults and children with diabetes mellitus. It also provides Toustar pen, along with dedicated Toujeo cartridges, addressing the need for a reusable delivery device. Combiflam, its product, helps to reduce pain and inflammation in conditions like headache, muscle and joint pain, and also reduces fever. Its brands also include Cardace, Allegra, Avil and Frisium. The Company has its own manufacturing facility in Goa. It has around 12 contract manufacturing organizations.
- Revenue in INR (TTM)28.51bn
- Net income in INR6.03bn
- Incorporated1956
- Employees3.53k
- LocationSanofi India Ltd54/ASir Mathuradas Vasanji RoadAndheri EastMUMBAI 400072IndiaIND
- Phone+91 2 228032000
- Fax+91 2 228032846
- Websitehttps://www.sanofiindialtd.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jubilant Pharmova Ltd | 66.22bn | 378.60m | 106.38bn | 1.03k | 277.24 | -- | 18.15 | 1.61 | 2.42 | 2.42 | 415.43 | -- | -- | -- | -- | 64,045,440.00 | -- | 3.95 | -- | 4.78 | 67.64 | 66.57 | 0.5133 | 6.27 | -- | 1.36 | -- | 18.52 | 2.47 | -3.63 | -114.73 | -- | 10.74 | 10.76 |
| Eris Lifesciences Ltd | 18.61bn | 3.86bn | 117.97bn | 3.55k | 30.57 | -- | 21.74 | 6.34 | 28.36 | 28.36 | 136.57 | -- | -- | -- | -- | 5,245,254.00 | -- | 17.62 | -- | 20.12 | 82.02 | 80.57 | 20.36 | 27.34 | -- | 7.94 | -- | -- | 25.10 | 14.52 | -5.90 | 5.38 | 101.87 | -- |
| Sun Pharma Advanced Research Co Ltd | 1.07bn | -3.63bn | 119.57bn | 407.00 | -- | -- | -- | 112.08 | -11.22 | -11.22 | 3.29 | -- | -- | -- | -- | 2,621,133.00 | -- | -59.13 | -- | -119.29 | 75.21 | 79.70 | -340.66 | -116.46 | -- | -400.34 | -- | -- | 73.98 | 25.00 | -9.43 | -- | -13.96 | -- |
| Astrazeneca Pharma India Ltd | 11.97bn | 1.39bn | 132.13bn | 947.00 | 94.86 | -- | 85.39 | 11.04 | 55.72 | 55.72 | 478.78 | -- | -- | -- | -- | 12,640,230.00 | -- | 10.51 | -- | 18.10 | 59.93 | 58.05 | 11.64 | 9.11 | -- | 132.84 | -- | 11.82 | 24.50 | 11.89 | 61.19 | 30.82 | 6.29 | -- |
| Concord Biotech Ltd | 9.71bn | 3.05bn | 159.99bn | -- | 53.18 | -- | 44.61 | 16.48 | 28.76 | 28.76 | 92.74 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 79.70 | -- | 31.38 | -- | -- | -- | -- | -- | 19.67 | -- | 37.25 | -- | -- | -- |
| Suven Pharmaceuticals Ltd | 11.68bn | 3.71bn | 161.47bn | 1.17k | 43.52 | -- | 38.44 | 13.83 | 14.58 | 14.58 | 45.91 | -- | -- | -- | -- | 10,023,860.00 | -- | -- | -- | -- | 58.68 | -- | 31.76 | -- | -- | 86.09 | -- | -- | 1.52 | -- | -9.37 | -- | -- | -- |
| Natco Pharma Ltd. | 38.28bn | 12.78bn | 176.76bn | 3.98k | 13.93 | -- | 12.19 | 4.62 | 70.84 | 70.84 | 212.24 | -- | -- | -- | -- | 9,621,513.00 | -- | 10.34 | -- | 12.04 | 78.26 | 75.11 | 33.38 | 22.66 | -- | 90.50 | -- | 21.34 | 39.20 | 4.22 | 320.76 | 0.5428 | -19.11 | -8.34 |
| Piramal Pharma Ltd | 77.82bn | -333.40m | 186.49bn | 6.30k | -- | -- | 26.81 | 2.40 | -0.3002 | -0.3002 | 63.15 | -- | -- | -- | -- | 12,362,800.00 | -- | -- | -- | -- | 64.29 | -- | -0.4284 | -- | -- | 6.36 | -- | -- | 7.97 | -- | -149.60 | -- | -- | -- |
| Piramal Enterprises Ltd | 79.98bn | -20.16bn | 187.23bn | 12.22k | -- | -- | -- | 2.34 | -90.77 | -90.77 | 339.88 | -- | -- | -- | -- | 6,545,270.00 | -- | 3.41 | -- | 4.51 | 47.29 | 88.04 | -25.21 | 26.30 | -- | 0.2287 | -- | 22.74 | 6.82 | -4.74 | 528.31 | 14.25 | -24.79 | 4.90 |
| Pfizer Ltd | 22.19bn | 5.02bn | 188.22bn | 1.70k | 37.49 | -- | 32.62 | 8.48 | 109.76 | 109.76 | 485.08 | -- | -- | -- | -- | 13,038,660.00 | -- | 13.81 | -- | 17.63 | 63.08 | 61.21 | 22.63 | 23.22 | -- | 50.30 | -- | 84.31 | -7.13 | 4.13 | 1.86 | 11.62 | -8.75 | 11.84 |
| Alembic Pharmaceuticals Ltd | 61.18bn | 5.90bn | 189.80bn | 14.59k | 32.16 | -- | 21.65 | 3.10 | 30.02 | 30.02 | 311.22 | -- | -- | -- | -- | 4,192,490.00 | -- | 11.45 | -- | 15.39 | 71.10 | 66.43 | 9.80 | 13.65 | -- | 10.21 | -- | 25.26 | 6.54 | 12.54 | -34.35 | -3.69 | -11.61 | 14.87 |
| Sanofi India Ltd | 28.51bn | 6.03bn | 193.44bn | 3.53k | 32.09 | 19.05 | 30.11 | 6.78 | 261.78 | 261.78 | 1,237.96 | 440.80 | 1.51 | 2.24 | 21.86 | -- | 31.84 | 22.42 | 50.35 | 30.21 | 57.88 | 55.69 | 21.15 | 21.03 | 0.897 | 449.47 | 0.0184 | 58.18 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Laurus Labs Ltd | 49.82bn | 1.88bn | 238.84bn | 5.75k | 127.50 | -- | 41.94 | 4.79 | 3.48 | 3.48 | 92.17 | -- | -- | -- | -- | 8,659,934.00 | -- | 11.78 | -- | 19.75 | 51.73 | 48.41 | 4.02 | 14.16 | -- | 2.50 | -- | 12.37 | 22.39 | 23.90 | -4.52 | 36.36 | 20.42 | 31.95 |
| Ajanta Pharma Ltd | 40.36bn | 7.36bn | 260.01bn | 7.71k | 35.45 | -- | 29.89 | 6.44 | 58.24 | 58.24 | 319.08 | -- | -- | -- | -- | 5,233,334.00 | -- | 16.13 | -- | 19.52 | 74.16 | 74.01 | 18.23 | 19.22 | -- | 100.64 | -- | 15.93 | 12.02 | 11.92 | -17.50 | 4.64 | -7.86 | -- |
| J B Chemicals and Pharmaceuticals Ltd | 33.85bn | 5.14bn | 278.54bn | 5.10k | 55.00 | -- | 43.29 | 8.23 | 32.63 | 32.63 | 214.87 | -- | -- | -- | -- | 6,643,323.00 | -- | 15.37 | -- | 18.18 | 65.83 | 60.20 | 15.19 | 15.49 | -- | 15.00 | -- | 31.73 | 29.91 | 17.36 | 6.35 | 24.26 | 83.84 | 54.75 |
| Syngene International Ltd | 35.66bn | 5.00bn | 284.87bn | 6.85k | 57.10 | -- | 31.28 | 7.99 | 12.45 | 12.45 | 88.72 | -- | -- | -- | -- | 5,208,267.00 | -- | 8.80 | -- | 11.95 | 71.36 | 70.68 | 14.03 | 17.00 | -- | 6.88 | -- | -- | 22.61 | 17.54 | 17.33 | 8.74 | 7.34 | 0.00 |
Data as of Apr 19 2024. Currency figures normalised to Sanofi India Ltd's reporting currency: Indian Rupee INR
21.99%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2023 | 1.37m | 5.95% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Mar 2024 | 903.03k | 3.92% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Mar 2024 | 833.46k | 3.62% |
| HDFC Life Insurance Co. Ltd. (Investment Portfolio)as of 30 Jun 2023 | 441.84k | 1.92% |
| SBI Funds Management Ltd.as of 31 Mar 2024 | 413.56k | 1.80% |
| Bajaj Allianz Life Insurance Co. Ltd.as of 30 Jun 2023 | 381.77k | 1.66% |
| The Vanguard Group, Inc.as of 29 Feb 2024 | 353.12k | 1.53% |
| Matthews International Capital Management LLCas of 31 Mar 2023 | 123.66k | 0.54% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 122.96k | 0.53% |
| Bajaj Finserv Asset Management Ltd.as of 31 Mar 2024 | 121.80k | 0.53% |
More ▼
Data from 31 Dec 2023 - 11 Apr 2024Source: FactSet Research Systems Inc.
